Search alternatives:
significant sources » significant source (Expand Search), significant burden (Expand Search), significant burdens (Expand Search)
sources decrease » resources increase (Expand Search), scores decreased (Expand Search), sizes decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant sources » significant source (Expand Search), significant burden (Expand Search), significant burdens (Expand Search)
sources decrease » resources increase (Expand Search), scores decreased (Expand Search), sizes decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
101
A set of 5 criteria for the needs of multi-criteria evaluation–combination A.
Published 2024Subjects: -
102
-
103
-
104
-
105
-
106
-
107
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
108
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
109
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
110
-
111
Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b>
Published 2025“…In addition, genetic variation in age-related plasticity in exploration contributed to a decrease in the magnitude of genetic correlations during the adult stage. …”
-
112
-
113
-
114
-
115
-
116
-
117
-
118
Pie charts showing the different patterns of risk factors associated with total colony losses.
Published 2025Subjects: -
119
<b>The loss of insulin-positive cell clusters precedes the decrease of islet frequency and beta cell area in type 1 diabetes</b>
Published 2025“…Moreover, changes in endocrine composition also occurred in mAAb+ donors, including a significant decrease in the INS+ islet fraction. …”
-
120